Abstract
While immune hemolysis due to donor isohemagglutinin (IH) production often complicates minor ABO incompatible peripheral blood hematopoietic stem cell transplantation (PBSCT), it is not known if this occurs with umbilical cord blood transplantation (UCBT). We compared IH production and hemolysis following minor ABO allogeneic PBSCT and UCBT. We reviewed 24 ABO minor incompatible allogeneic PBSCTs and 14 ABO minor incompatible UCBTs. Patients were evaluated for donor-derived IH by reverse ABO grouping. Evaluation of hemolysis was based on clinical and laboratory findings of anemia associated with increased RBC transfusion need, concomitant with the appearance of donor-derived IH. Of the 24 ABO minor incompatible allogeneic PBSCTs, 15 produced donor-derived IH from 6 to 88 days following transplantation, with seven of 15 patients exhibiting clinically evident hemolysis. There was no significant difference in days to leukocyte engraftment or infused CD34 cells in patients with or without donor-derived IH. None of the 14 patients receiving ABO incompatible UCBTs showed evidence of donor-derived IH following transplantation with a median follow-up of 60 days. We conclude that donor IHs are not produced in patients undergoing minor ABO incompatible UCBTs suggesting fundamental immunologic differences between allogeneic PBSCT and UCBT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Worel N, Greinix HT, Keil F, Mitterbauer M, Lechner K, Fischer G et al. Severe immune hemolysis after minor ABO-mismatched allogenic peripheral blood progenitor cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning. Transfusion 2002; 42: 1293–1301.
Rowley SD . Hematopoietic stem cell transplantation between red cell incompatible donor-recipient pairs. Bone Marrow Transplant 2001; 28: 315–321.
Salmon JP, Michaux S, Hermanne JP . Delayed massive hemolysis mediated by minor ABO incompatibility after allogenic peripheral blood progenitor cell transplantation. Transfusion 1999; 39: 824–827.
Oziel S, Barbey C, Chabannon C . Early and fatal immune hemolysis after so called minor ABO incompatible peripheral blood stem cell allotransplantation. Bone Marrow Transplant 1997; 19: 1155–1156.
Toren A, Dacosta Y, Manny N, Varadi G, Or R, Nagler A . Passenger B-lymphocyte induced severe hemolytic disease after allogenic peripheral blood stem cell transplantation. Blood 1996; 87: 843–844.
Forman SJ, Blume KG, Thomas ED . Bone Marrow Transplantation. Blackwell Scientific Publications: Boston, 1994.
Laurencet FM, Samii K, Bressoud A, Tajeddin M, Easton J, Stelling MJ et al. Massive delayed hemolysis following peripheral blood stem cell transplantation with minor ABO incompatibility. Hematol Cell Ther 1997; 39: 159–162.
Mollison PL, Engelfriet CP, Contreras M . Blood Transfusion in Clinical Medicine, 10th edn. Blackwell Science: Oxford, 1997 pp. 79–80, 123–124.
Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. New Engl J Med 2001; 344: 1815–1822.
Sobocinski KA, Horowitz MM, Rowlings PA, Zhang MJ, Nugent ML, Passweg JR et al. Bone Marrow Transplantation – 1994: a report from the International Bone Marrow Transplant Registry and the North American Autologous Bone Marrow Transplant Registry. J Hematother 1994; 3: 95–102.
Applebaum FR, Clift R, Buckner CD, Anasetti C, Radich J, Higano T et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia. Med Oncol 1994; 11: 69–74.
Copelan EA, Biggs JC, Szer J, Thompson JM, Crilley P, Brodsky I et al. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia and multiple myeloma following preparation with busulfan and cyclophosfamide (BuCy2). Semin Oncol 1993; 20 (4 Suppl 4): 33–38.
Blume KG, Kopecky KJ, Henslee-Downey JP, Forman SJ, Stiff PJ, LeMaistre CF et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosfamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. Blood 1993; 81: 2187–2193.
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.
Flowers ME, Kansu E, Sullivan KM . Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am 1999; 13: 1091–1112.
Laughlin MJ . Umbilical cord blood for allogeneic transplantation in children and adults. Bone Marrow Transplant 2001; 27: 1–6.
Gajewaski JL, Petz LD, Calhoun L . Hemolysis of transfused group O red blood cells in minor ABO- incompatible unrelated donor bone marrow transplants in patients receiving cyclosporin without posttransplant methotrexate. Blood 1992; 79: 3076–3085.
Bolan CD, Childs RW, Procter JL, Barrett AJ, Leitman SF . Massive immune hemolysis after allogenic peripheral blood stem cell transplantation with minor ABO incompatibility. Br J Haematol 2001; 112: 787–795.
Ramsey G, Nusbacher J, Starzl TE, Lindsay GD . Isohemagglutinins of graft origin after ABO-unmatched liver transplantation. New Engl J Med 1984; 311: 1167–1170.
Sniecinski IJ, O'Donnell MR . Hemolytic complications of hematopoietic cell transplantation. In: Thomas ED, Blume KG, Forman SJ (eds). Hematopoietic Cell Transplantation. Blackwell Science: Malden, 1999, pp. 674–684.
Greeno EW, Perry EH . Exchange transfusion the hard way: massive hemolysis following transplantation of bone marrow with minor ABO incompatibility. Transfusion 1996; 36: 71–74.
Hows J, Beddow K, Smith E . Donor derived red blood cell antibodies and immune hemolysis after allogenic bone marrow transplantation. Blood 1986; 67: 177–181.
Theilgaard-Monch K, Jensen KR, Palm H . Flow cytometric assessment of lymphocyte subsets, lymphoid progenitors, and hematopoietic stem cells in allogenic stem cell grafts. Bone Marrow Transplant 2001; 28: 1073–1082.
Agematsu K . Memory B cells and CD27. Histol Histopathol 2000; 15: 573–576.
Lee HJ, Lee HJ, Choi SJ, Kim S, Seol M, Kwon SW et al. Changes in isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation. Br J Haematol 2003; 120: 702–710.
Paloczi K, Batai A, Gopcsa L . Immunophenotypic characterization of cord blood B-lymphocytes. Bone Marrow Transplant 1998; 22 (Suppl. 4): S89–S91.
Benjamin RJ, McGurk S, Ralston MS, Churchill WH, Antin JH . ABO incompatibility as an adverse risk factor for survival after allogenic bonemarrow transplantation. Transfusion 1999; 39: 179–187.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Snell, M., Chau, C., Hendrix, D. et al. Lack of isohemagglutinin production following minor ABO incompatible unrelated HLA mismatched umbilical cord blood transplantation. Bone Marrow Transplant 38, 135–140 (2006). https://doi.org/10.1038/sj.bmt.1705409
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705409
Keywords
This article is cited by
-
ABO incompatibility does not influence transfusion requirements in patients undergoing single-unit umbilical cord blood transplantation
Bone Marrow Transplantation (2017)
-
IgM anti-recipient ABO antibodies predict acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation
International Journal of Hematology (2013)
-
Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation
Bone Marrow Transplantation (2011)